Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.
Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.
Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.
The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy to standard sorafenib treatment compared with using sorafenib alone.
Scientists at the University of Delaware and the University of Illinois at Chicago have found a new way to kill liver cancer cells and inhibit tumor growth. First, they silence a key cellular enzyme, and then they add a powerful drug.
Researchers at the Institute of Industrial Science, the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel formation and drugs targeting this event.
Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.
Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to patients who start on the full dose.
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Treatment options for liver cancer are often limited and almost exclusively involve transplantation if possible, or local chemoembolization and radiofrequency ablation.
Columbia University Medical Center researchers have created a computational tool that can rapidly predict which genes are implicated in an individual's cancer and recommend treatments.
The most common type of liver cancer, called Hepatocellular carcinoma, is one of the most prevalent tumours worldwide.
Renal cell carcinoma is the most common type of kidney cancer, and African-Americans and males appear most at risk for this disease that can be asymptomatic until it has spread and become highly lethal, said Dr. Vinata B. Lokeshwar, cancer researcher and chair of the Department of Biochemistry and Molecular Biology at the Medical College of Georgia at Augusta University.